Case series and clinical reports in lymphoma and multiple myeloma indicate that anti-CD19 and anti-BCMA CAR-T therapies can be administered safely without compromising viral control, provided that ART is maintained and carefully monitored [53,100,101]. This evidence concerns the gene TNFRSF17 and lymphoma.